ANI Pharmaceuticals (ANIP) reported $247.06 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 29.6%. EPS of $2.33 for the same period compares to $1.63 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $232.98 million, representing a surprise of +6.04%. The company delivered an EPS surprise of +17.32%, with the consensus EPS estimate being $1.99.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total Net Revenues- Rare Disease: $131.27 million versus the five-analyst average estimate of $132.69 million.
- Net Revenues- Rare Disease and Brands - ILUVIEN and YUTIQ: $19.84 million compared to the $18.65 million average estimate based on five analysts.
- Net Revenues- Rare Disease and Brands - Cortrophin Gel: $111.43 million versus $114.06 million estimated by five analysts on average.
- Net Revenues- Generic pharmaceutical products: $100.76 million versus $86.36 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +28.2% change.
- Net Revenues- Brands: $12.32 million versus the two-analyst average estimate of $11.07 million.
- Total Net Revenues- Generics and Other: $103.47 million versus the two-analyst average estimate of $91.74 million.
- Total Net Revenues- Rare Disease and Brands: $143.59 million compared to the $144.19 million average estimate based on two analysts. The reported number represents a change of +34.3% year over year.
- Net Revenues- Royalties and other pharmaceutical services: $2.71 million versus the two-analyst average estimate of $3.2 million.
View all Key Company Metrics for ANI here>>>
Shares of ANI have returned -5.9% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
